Description

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C84H140N14O18S.xC2HF3O2—Food Res Int. 10 October 2022, 112029.|J Ethnopharmacol. 2024 Jan 24:117824.|Int J Med Sci. 2022 Feb.-[1]Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.|[2]William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.—-1666.16 (free acid)–99.76–[S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF (TFA salt)]–Infection–H2O : 50 mg/mL (ultrasonic)–Antibiotic;HSV;MMP;Toll-like Receptor (TLR)–HSV-2;MMP-9;TLR2;TLR6–Anti-infection;Immunology/Inflammation;Metabolic Enzyme/Protease–Peptides